Formycon and Fresenius Kabi secure UK approval for Otulfi, a ustekinumab biosimilar targeting inflammatory conditions.

Marks the Third Year Since the Launch of the First US Biosimilar Market ReportINCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx) is now available. These ...